Toremfine by Dragon Pharma

Dragon Pharma Antiestrogen / PCT

Toremifene Citrate

Toremfine / Fareston•20 mg/tab

Class Third-Generation SERM

Half-Life ~5–6 days

Pack 100 tabs

FDA Approval Yes — Breast Cancer / Prostate (Men)

Genotoxic Risk Lower than Tamoxifen

Form Oral Tablet

Toremifene Citrate (Toremfine) — Third-Generation SERM by Dragon Pharma

Toremifene Citrate (Toremfine, Fareston) is Dragon Pharma's formulation of the third-generation Selective Estrogen Receptor Modulator at 20mg per tablet — a structural analogue of Tamoxifen developed specifically to retain full SERM activity while reducing the genotoxic metabolites produced by Tamoxifen's hepatic metabolism. Toremifene is FDA-approved for breast cancer treatment and has been investigated specifically for prostate cancer prevention in men, making it the SERM with the most developed male-specific clinical data set. For AAS users, Toremifene offers the same PCT mechanism as Tamoxifen but with a safety profile that distinguishes it for men concerned with long-term use.

Also searched as: Toremifene Citrate 20mg, Toremfine, Fareston, Toremifene SERM PCT, Dragon Pharma Toremifene.

Toremifene vs Tamoxifen — The Structural Difference That Matters

Toremifene and Tamoxifen are structurally nearly identical — but one modification changes the safety calculus significantly:

Toremifene differs from Tamoxifen by a single chlorine atom added to the ethyl side chain. This chlorination is not cosmetic — it fundamentally alters the hepatic metabolic pathway of the molecule
Tamoxifen undergoes CYP3A4-mediated oxidation to form 3,4-epoxytamoxifen and α-hydroxytamoxifen — reactive intermediates that are genotoxic, capable of forming DNA adducts (covalent bonds with DNA) in liver tissue. These DNA adducts have been identified as the mechanism behind Tamoxifen's known (rare but documented) association with liver carcinogenicity in animal models and endometrial cancer risk in women
The chlorination of Toremifene blocks this specific metabolic pathway — CYP3A4 cannot form the same genotoxic epoxide intermediates from Toremifene that it produces from Tamoxifen. Toremifene does not produce detectable DNA adducts in liver tissue at therapeutic doses in multiple studies
The ERα antagonism — the mechanism responsible for both PCT effectiveness and gynecomastia prevention — is essentially equivalent between Toremifene and Tamoxifen at appropriate doses

Toremifene's Male-Specific Clinical Data

This is the information gap that most competitor content leaves entirely unfilled:

FDA-approved for breast cancer: Toremifene (Fareston, Orion) received FDA approval for treatment of metastatic breast cancer in postmenopausal women — providing the regulatory foundation and extensive safety data of a fully approved pharmaceutical
RADAR/REDEEM prostate cancer trials in men: Toremifene was specifically studied in men in the REDEEM trial — a Phase III randomised controlled trial investigating whether Toremifene could prevent progression from high-grade prostatic intraepithelial neoplasia (HGPIN) to prostate cancer in men. This makes Toremifene uniquely the SERM with a completed Phase III trial specifically in a male population, generating male pharmacokinetic and safety data that Tamoxifen's clinical history (primarily female breast cancer) does not provide
The REDEEM trial used 20mg/day Toremifene in men — the same dose range relevant for AAS PCT — establishing tolerability in the male-specific context

SERM Comparison — Toremifene's Position

Parameter	Toremifene (Toremfine)	Tamoxifen (Nolvadex)	Clomiphene (Clomid)
Generation	Third	First	First
Genotoxic metabolites	None detected — chlorination blocks pathway	Epoxide intermediates; DNA adducts in liver	No major genotoxic metabolites identified
ERα antagonism (breast/HPG)	Equivalent to Tamoxifen	Standard reference	Good — bilateral ER blockade
Male clinical trial data	Phase III REDEEM trial at 20mg/day in men	Primarily female breast cancer data	Male fertility and PCT history
Lipid effects	Favourable — LDL reduction, HDL preservation	Modest lipid benefit	Variable
FDA approval	Breast cancer (Fareston)	Breast cancer (Nolvadex)	Female infertility (Clomid)
Half-life	~5–6 days	~5–7 days (parent); ~14 days (Endoxifen)	~5–7 days (mixed isomers)

PCT Mechanism — How Toremifene Restores the HPG Axis

The PCT mechanism is identical to Tamoxifen and Clomid — ERα antagonism at the hypothalamus and pituitary:

Estrogen exerts negative feedback on the HPG axis by binding ERα at the hypothalamus (suppressing GnRH) and pituitary (suppressing LH and FSH release). After an AAS cycle, elevated estrogen (from aromatisation of residual testosterone as exogenous AAS clears) sustains this suppression
Toremifene blocks ERα at the hypothalamus and pituitary — removing this estrogen negative feedback signal. GnRH pulsatility resumes, driving LH and FSH recovery, which stimulates Leydig cell testosterone production
Toremifene's ERα antagonism in breast tissue simultaneously provides gynecomastia protection during PCT
The equivalent efficacy to Tamoxifen at comparable doses means Toremifene produces the same magnitude of LH/FSH stimulation with a potentially improved long-term safety profile

Lipid Profile Advantage

One practical advantage of Toremifene over AIs in the PCT context:

AAS cycles — particularly those including 17-AA oral compounds — negatively impact lipid profiles (LDL elevation, HDL reduction). AIs used on-cycle worsen this further by eliminating estrogen's cardioprotective effects on lipids
Toremifene, like Tamoxifen, acts as an estrogen agonist in hepatic tissue — producing favourable lipid effects including LDL reduction and HDL preservation. Studies in the REDEEM trial population demonstrated Toremifene's lipid benefits in men
Transitioning from on-cycle AI to Toremifene-based PCT therefore provides lipid recovery support alongside HPG axis restart

Effects and Benefits

HPG axis ERα antagonism — LH and FSH stimulation through hypothalamic/pituitary estrogen feedback removal; equivalent to Tamoxifen
Gynecomastia prevention — breast tissue ERα blockade
Reduced genotoxic metabolite production — key long-term safety distinction from Tamoxifen
Favourable lipid profile — hepatic ER agonism; LDL reduction and HDL preservation
Male-specific clinical data — Phase III REDEEM trial at 20mg/day in men

Dosage and Administration

Protocol	Dose	Duration	Notes
PCT (standard)	60mg/day → 40mg/day → 20mg/day	Week 1 at 60mg; weeks 2-3 at 40mg; weeks 4-6 at 20mg	Higher doses than Tamoxifen needed — different ERα binding kinetics
Gynecomastia prevention on-cycle	20–40 mg/day	Throughout cycle as needed	Same breast ERα blockade mechanism as Tamoxifen

Note: Toremifene requires higher doses than Tamoxifen to achieve equivalent ERα blockade because Toremifene — unlike Tamoxifen — is not significantly converted to a higher-potency metabolite equivalent to Endoxifen. Where Tamoxifen's active metabolite Endoxifen is 30-100× more potent than the parent, Toremifene's activity is more directly driven by the parent compound at its plasma concentration. Standard Toremifene PCT dosing uses 60mg/day initially (versus Tamoxifen's 40mg/day) to achieve comparable ERα occupancy.

PCT Combination Context

Clomid — combined SERM PCT; Toremifene + Clomid at reduced individual doses covers HPG axis at complementary receptor binding profiles
HCG 5000IU — Leydig cell maintenance pre-PCT or during cycle; same complementary role as with Tamoxifen-based PCT

Currently out of stock. See Nolvadex (Tamoxifen Citrate) as the available SERM alternative for PCT.

"Toremifene's chlorinated structure eliminates the genotoxic epoxide metabolites produced by Tamoxifen's hepatic metabolism — with equivalent HPG axis ERα blockade and the only SERM with a completed Phase III trial specifically in men at 20mg/day, it represents the most pharmacologically refined SERM option for male AAS users."

Storage and Handling

Store Toremifene at room temperature, away from direct sunlight and moisture. Keep in original packaging until use.

Please log in to write review.

Structurally, Toremifene differs from Tamoxifen by a single chlorine atom on the ethyl side chain. This chlorination fundamentally alters hepatic metabolism: Tamoxifen undergoes CYP3A4 oxidation to genotoxic intermediates (3,4-epoxytamoxifen and α-hydroxytamoxifen) that form DNA adducts in liver tissue — the proposed mechanism behind Tamoxifen's rare but documented liver carcinogenicity risk in animal models. Toremifene's chlorination blocks this specific metabolic pathway; no DNA adducts are detected in liver tissue at therapeutic doses. The ERα antagonism responsible for PCT effectiveness is essentially equivalent between both compounds.

Tamoxifen derives much of its ERα blocking potency from its active metabolite Endoxifen — produced via CYP2D6 conversion — which binds ERα with 30-100× greater affinity than Tamoxifen itself. Toremifene does not produce an equivalent high-potency metabolite; its activity is driven more directly by the parent compound at its plasma concentration. To achieve comparable ERα occupancy at hypothalamic and pituitary receptors, Toremifene requires higher doses — standard PCT protocols use 60mg/day initially (versus Tamoxifen's 40mg/day) rather than simple milligram equivalence.

REDEEM (Reduction by Dutasteride of Clinical Progression Events in Expectant Management) — more accurately the GTx Toremifene REDEEM study — was a Phase III randomised controlled trial investigating Toremifene at 20mg/day in men with high-grade prostatic intraepithelial neoplasia, examining prevention of prostate cancer progression. This trial specifically enrolled men and used the same dose range relevant for AAS PCT, generating pharmacokinetic and safety data in male subjects. This is unique — Tamoxifen's extensive clinical data comes predominantly from female breast cancer populations, making Toremifene the only SERM with a completed Phase III trial specifically in men at PCT-relevant doses.

Yes — its ERα antagonism in breast tissue is equivalent to Tamoxifen for gynecomastia prevention. 20-40mg/day during cycle provides the same breast tissue ERα blockade. For systemic estrogen management (water retention, mood effects from aromatisation), an aromatase inhibitor remains necessary — Toremifene blocks estrogen receptors but does not reduce estrogen production, identical in this respect to Tamoxifen.

Practically yes — AAS cycles and the preceding AI use both negatively impact lipid profiles. Toremifene, like Tamoxifen, acts as a hepatic ER agonist, producing favourable lipid effects: LDL reduction and HDL preservation, documented in the REDEEM trial population. Transitioning from an AI to Toremifene-based PCT therefore provides simultaneous HPG axis restart and partial lipid profile recovery — a meaningful secondary benefit during the post-cycle period when lipid normalisation is a priority.

Stock availability varies. While Toremifene is unavailable, Nolvadex (Tamoxifen Citrate) provides equivalent HPG axis ERα blockade for PCT and gynecomastia prevention through the same SERM mechanism — with the addition of Endoxifen's high-potency active metabolite. For users specifically seeking Toremifene's reduced genotoxic metabolite profile, monitoring restock is advisable; for immediate PCT needs, Nolvadex at standard doses provides equivalent functional coverage.